2008
DOI: 10.1002/chir.20666
|View full text |Cite
|
Sign up to set email alerts
|

Enantioselective plasma protein binding of propafenone: Mechanism, drug interaction, and species difference

Abstract: The interaction of propafenone (PPF) enantiomers with human plasma, human serum albumin (HSA), alpha(1)-acid glycoprotein (AGP), as well as with plasma from rat, rabbit, and cow was investigated using indirect chiral high performance liquid chromatography (HPLC) and ultrafiltration techniques. The stronger binding of the S-PPF found in human plasma was due to AGP. Two classes of binding sites in AGP were identified: one with high-affinity and small binding capacity (K(1(S)) = 7.65 x 10(6) M(-1), n(1(S)) = 0.50… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
21
0
1

Year Published

2009
2009
2020
2020

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 20 publications
(25 citation statements)
references
References 22 publications
(30 reference statements)
3
21
0
1
Order By: Relevance
“…Over 50% of the drugs in current clinical use are chiral, and the majority of synthetically derived chiral drugs are administered as mixtures of the constituent stereoisomers (most commonly the racemate) [2] . In addition to stereoselective metabolism, stereoselective protein binding might also be responsible for the differences in pharmacokinetics between enantiomers [3][4][5] . Studies on the mechanism of stereoselective binding to HSA may better explain the different pharmacokinetics between enantiomers.…”
Section: Introductionmentioning
confidence: 99%
“…Over 50% of the drugs in current clinical use are chiral, and the majority of synthetically derived chiral drugs are administered as mixtures of the constituent stereoisomers (most commonly the racemate) [2] . In addition to stereoselective metabolism, stereoselective protein binding might also be responsible for the differences in pharmacokinetics between enantiomers [3][4][5] . Studies on the mechanism of stereoselective binding to HSA may better explain the different pharmacokinetics between enantiomers.…”
Section: Introductionmentioning
confidence: 99%
“…For the current drugs, the observed value of fu p ranged from 0.0007 to 0.15, whereas human CL ranged from 0.04 to 15 mL/(min kg), covering a large range of properties for highly bound compounds. 2,10,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] The dataset is compiled in Table 1. Clearance refers to plasma kinetics, and it was assumed that this is mainly due to hepatic metabolic CL.…”
Section: Datasetsmentioning
confidence: 99%
“…For each drug studied, the main extracellular binding protein considered in this study is AL or AAG [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] (Table 1). However, the works of Burczynski et al, 13 Qin et al, 38 and Bilello et al 39 suggest that proteinfacilitated metabolism, and hence hepatocyte uptake of drugs, is significantly greater with AL as compared with that of AAG at physiologically relevant concentrations (more explanations are provided in the Discussion section for differences between AL and AAG).…”
Section: Estimation Of Plr Valuementioning
confidence: 99%
“…Since the binding of drugs to plasma proteins can be stereoselective [11,12], the present study describes, for the first time, the analysis of unbound concentrations of the tramadol, M1 and M2 enantiomers in human plasma and the application of this method to pharmacokinetic studies on patients with neuropathic pain treated with a single dose of racemic tramadol. The method described is derived from a study recently published by our group in which total concentrations of the tramadol, M1 and M2 enantiomers were analyzed in rat plasma [13].…”
Section: Introductionmentioning
confidence: 99%